<DOC>
	<DOCNO>NCT03035032</DOCNO>
	<brief_summary>The objective study evaluate safety , efficacy , impact quality life ( QoL ) ELIGARD速 hormone-dependent prostate cancer patient Asia .</brief_summary>
	<brief_title>A Study ELIGARD速 Hormone-dependent Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>A patient physician decide initiate treatment Luteinizing Hormone Releasing Hormone ( LHRH ) agonist standard clinical practice Biopsyproven prostate adenocarcinoma Locally advance prostate cancer biochemical relapse radical prostatectomy radiotherapy . Hormonal treatmentnaive advance metastatic prostate cancer patient receive chemotherapy plan undergo treatment chemotherapy study entry . Patient indicate study complete , expect access androgen deprivation therapy ( ADT ) , either medical surgical , within local healthcare system ( either public/ private health insurance pocket payment ) . Patient castrate resistant prostate cancer Patient previously underwent bilateral orchiectomy Patient receive prior treatment LHRH analogues Prior concomitant treatment systemic chemotherapy . A patient likelihood receive systemic chemotherapy enrol Life expectancy &lt; 1 year due comorbidities Participation another interventional clinical trial within one month prior study entry duration study Patient plan receive intermittent ADT time study entry Patient receive nonpalliative radiotherapy within 3 month prior study entry Patient receive adjuvant ADT combination definitive radiotherapy Patient metastatic hormonal treatmentnaive prostate cancer , chemohormonal treatment ( combination Docetaxel ADT ) indicate . Patient hypersensitivity gonadotropin release hormone ( GnRH ) , GnRH agonist analogs component ELIGARD速 Patient contraindication ELIGARD速 use base local prescribing information</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leuprolide acetate</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>